Universe Pharmaceuticals Receives Nasdaq Delisting Notice
Ticker: UPC · Form: 6-K · Filed: Feb 3, 2025 · CIK: 1809616
| Field | Detail |
|---|---|
| Company | Universe Pharmaceuticals INC (UPC) |
| Form Type | 6-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, nasdaq, regulatory-filing
Related Tickers: URPH
TL;DR
Nasdaq wants to kick Universe Pharma off the exchange, but they can fight it.
AI Summary
Universe Pharmaceuticals INC received a Nasdaq delisting notice on February 3, 2025, indicating potential delisting from the Nasdaq Capital Market. The company has the option to request a hearing with the Nasdaq Listing Qualifications Department to present its case.
Why It Matters
This notice signifies a critical juncture for Universe Pharmaceuticals, as delisting could severely impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — Receiving a delisting notice from a major exchange like Nasdaq presents a significant risk to the company's operations and stock value.
Key Players & Entities
- Universe Pharmaceuticals INC (company) — Filer of the 6-K report and recipient of the delisting notice.
- Nasdaq (company) — Exchange that issued the delisting notice.
- February 3, 2025 (date) — Date the 6-K report was filed and the delisting notice was received.
FAQ
What is the primary reason for the Nasdaq delisting notice?
The filing does not explicitly state the reason for the delisting notice, only that one was received.
What is Universe Pharmaceuticals' recourse after receiving the delisting notice?
Universe Pharmaceuticals has the option to request a hearing with the Nasdaq Listing Qualifications Department.
When was this 6-K report filed?
This 6-K report was filed on February 3, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China.
Does Universe Pharmaceuticals file annual reports under Form 20-F or 40-F?
Universe Pharmaceuticals indicates it files annual reports under Form 20-F.
Filing Stats: 159 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2025-02-03 16:10:04
Filing Documents
- ea0229300-6k_universe.htm (6-K) — 14KB
- ea022930001ex99-1_universe.htm (EX-99.1) — 9KB
- 0001213900-25-009434.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Universe Pharmaceuticals INC. Date: February 3, 2025 By: /s/ Gang Lai Gang Lai Chief Executive Officer 2